Everhart Financial Group Inc. Invests $229,000 in Axon Enterprise, Inc. (NASDAQ:AXON)

Everhart Financial Group Inc. purchased a new position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 436 shares of the biotechnology company's stock, valued at approximately $229,000.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock worth $5,019,886,000 after buying an additional 275,959 shares in the last quarter. Geode Capital Management LLC boosted its stake in Axon Enterprise by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock valued at $1,095,542,000 after acquiring an additional 65,097 shares during the period. Capital World Investors grew its stake in Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after buying an additional 841,772 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Axon Enterprise by 273.8% during the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after acquiring an additional 812,337 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $482,081,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the transaction, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. The trade was a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Julie A. Cullivan sold 657 shares of the company's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $700.00, for a total transaction of $459,900.00. Following the transaction, the director now owns 1,735 shares in the company, valued at approximately $1,214,500. The trade was a 27.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,662 shares of company stock valued at $29,739,909 in the last ninety days. Insiders own 4.40% of the company's stock.

Axon Enterprise Stock Performance

AXON stock traded up $13.74 during trading on Monday, reaching $794.37. 88,168 shares of the stock were exchanged, compared to its average volume of 714,030. The stock has a 50 day simple moving average of $669.47 and a 200-day simple moving average of $621.44. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a twelve month low of $279.02 and a twelve month high of $806.64. The company has a market capitalization of $61.84 billion, a P/E ratio of 205.26, a price-to-earnings-growth ratio of 5.17 and a beta of 1.29.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm's revenue for the quarter was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.15 earnings per share. As a group, sell-side analysts anticipate that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on AXON. Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. The Goldman Sachs Group raised their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Barclays increased their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Bank of America upped their target price on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Finally, Needham & Company LLC increased their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $699.55.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.